Physician profile
Nicholas Peterkin
NPI 1912211905
$552.15
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $388 · 2020: $153 · 2021: $11.93.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $109.31 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $90.90 | 2019-2020 | |
| Lilly USA, LLC | $66.35 | 2019-2020 | |
| Amarin Pharma, INC. | $48.50 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $37.99 | 2019-2020 | |
| Genentech USA, INC. | $36.42 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.55 | 2019-2020 | |
| Novo Nordisk INC | $23.34 | 2019-2020 | |
| Allergan, INC. | $16.57 | 2020 | |
| Ethicon US, LLC | $15.44 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.57 | 2019 | |
| Hologic Sales and Service, LLC | $13.37 | 2019 | |
| Pfizer INC. | $12.49 | 2019 | |
| Abbvie INC. | $11.93 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.41 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $11.01 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicholas Peterkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.